Reprint of "Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury" [Brain Behav. Immun. 21 (2007) 238-246]

Brain, Behavior, and Immunity

Volumn 21, Issue 5, 2007, Pages 677-685

  Tawfik, Vivianne L ^a,b   Nutile McMenemy, Nancy ^b,c   LaCroix Fralish, Michael L ^a,b   DeLeo, Joyce A ^a,b,c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Neuroscience Center at Dartmouth   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Astrocyte; Cytokine; Glia; Microglia; Neuropathic pain

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; METHYLXANTHINE DERIVATIVE; PROPENTOFYLLINE;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CHRONIC PAIN; CONTROLLED STUDY; DRUG EFFICACY; GLIA CELL; IMMUNOREACTIVITY; MALE; MICROGLIA; NONHUMAN; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD;

EID: 34249694111     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-1591(07)00095-5     Document Type: Article

References (44)

1. Abbadie C., Lindia J.A., Cumiskey A.M., Peterson L.B., Mudgett J.S., Bayne E.K., DeMartino J.A., MacIntyre D.E., and Forrest M.J. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc. Natl. Acad. Sci. USA 100 (2003) 7947-7952
2. Arruda J.L., Sweitzer S., Rutkowski M.D., and DeLeo J.A. Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain. Brain Res. 879 (2000) 216-225
3. Cherny N.I., Thaler H.T., Friedlander-Klar H., Lapin J., Foley K.M., Houde R., and Portenoy R.K. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology 44 (1994) 857-861
4. Clark, A.K., Gentry, C., Bradbury, E.J., McMahon, S.B., Malcangio, M., 2006. Role of spinal microglia in rat models of peripheral nerve injury and inflammation. Eur. J. Pain epub.
5. Colburn R.W., DeLeo J.A., Rickman A.J., Yeager M.P., Kwon P., and Hickey W.F. Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J. Neuroimmunol. 79 (1997) 163-175
6. Covino B.G., Dubner R., Gybels J., Losterlitz H.W., Liebeskind J.C., Sternbach R.A., Vylicky L., Yamamura H., and Zimmerman M. Ethical standards for investigations of experimental pain in animals. The Committee for Research and Ethical Issues of the International Association for the Study of Pain. Pain 9 (1980) 141-143
7. Coyle D.E. Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. Glia 23 (1998) 75-83
8. DeLeo J., Toth L., Schubert P., Rudolphi K., and Kreutzberg G.W. Ischemia-induced neuronal cell death, calcium accumulation, and glial response in the hippocampus of the Mongolian gerbil and protection by propentofylline (HWA 285). J. Cereb. Blood Flow Metab. 7 (1987) 745-751
9. DeLeo J.A., Colburn R.W., and Rickman A.J. Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res. 759 (1997) 50-57
10. DeLeo J.A., Tawfik V.L., and LaCroix-Fralish M.L. The tetrapartite synapse: path to CNS sensitization and chronic pain. Pain 122 (2006) 17-21
11. Dellemijn P.L., and Vanneste J.A. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 349 (1997) 753-758
12. Eriksson N.P., Persson J.K., Aldskogius H., and Svensson M. A quantitative analysis of the glial cell reaction in primary sensory termination areas following sciatic nerve injury and treatment with nerve growth factor in the adult rat. Exp. Brain Res. 114 (1997) 393-404
13. Fanciullo G.J., Ball P.A., Girault G., Rose R.J., Hanscom B., and Weinstein J.N. An observational study on the prevalence and pattern of opioid use in 25,479 patients with spine and radicular pain. Spine 27 (2002) 201-205
14. Giulian D., Li J., Leara B., and Keenen C. Phagocytic microglia release cytokines and cytotoxins that regulate the survival of astrocytes and neurons in culture. Neurochem. Int. 25 (1994) 227-233
15. Hains B.C., and Waxman S.G. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J. Neurosci. 26 (2006) 4308-4317
16. Haydon P.G. GLIA: listening and talking to the synapse. Nat. Rev. Neurosci. 2 (2001) 185-193
17. Kimelberg H.K. The problem of astrocyte identity. Neurochem. Int. 45 (2004) 191-202
18. Kittner B., Rossner M., and Rother M. Clinical trials in dementia with propentofylline. Ann. N Y Acad. Sci. 826 (1997) 307-316
19. Klein M.A., Moller J.C., Jones L.L., Bluethmann H., Kreutzberg G.W., and Raivich G. Impaired neuroglial activation in interleukin-6 deficient mice. Glia 19 (1997) 227-233
20. Kloss C.U., Bohatschek M., Kreutzberg G.W., and Raivich G. Effect of lipopolysaccharide on the morphology and integrin immunoreactivity of ramified microglia in the mouse brain and in cell culture. Exp. Neurol. 168 (2001) 32-46
21. Ledeboer A., Sloane E.M., Milligan E.D., Frank M.G., Mahony J.H., Maier S.F., and Watkins L.R. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 115 (2005) 71-83
22. Linderoth B., and Foreman R.D. Mechanisms of spinal cord stimulation in painful syndromes: role of animal models. Pain Med. 7 Suppl. 1 (2006) S14-S26
23. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
24. McRae A., Ling E.A., Schubert P., and Rudolphi K. Properties of activated microglia and pharmacologic interference by propentofylline. Alzheimer Dis. Assoc. Disord. 12 Suppl. 2 (1998) S15-S20
25. Meskini N., Nemoz G., Okyayuz-Baklouti I., Lagarde M., and Prigent A.F. Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. Biochem. Pharmacol. 47 (1994) 781-788
26. Nagata K., Ogawa T., Omosu M., Fujimoto K., and Hayashi S. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity. Arzneimittelforschung 35 (1985) 1034-1036
27. Narita M., Yoshida T., Nakajima M., Miyatake M., Takagi T., Yajima Y., and Suzuki T. Direct evidence for spinal cord microglia in the development of a neuropathic pain-like state in mice. J. Neurochem. 97 (2006) 1337-1348
28. Parkinson F.E., and Fredholm B.B. Effects of propentofylline on adenosine A1 and A2 receptors and nitrobenzylthioinosine-sensitive nucleoside transporters: quantitative autoradiographic analysis. Eur. J. Pharmacol. 202 (1991) 361-366
29. Raghavendra V., Tanga F., and DeLeo J.A. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 306 (2003) 624-630
30. Raghavendra V., Tanga F., Rutkowski M.D., and DeLeo J.A. Anti-hyperalgesic and morphine-sparing actions of propentofylline following peripheral nerve injury in rats: mechanistic implications of spinal glia and proinflammatory cytokines. Pain 104 (2003) 655-664
31. Rother M., Erkinjuntti T., Roessner M., Kittner B., Marcusson J., and Karlsson I. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Dement. Geriatr. Cogn. Disord. 9 Suppl. 1 (1998) 36-43
32. Schubert P., Ogata T., Miyazaki H., Marchini C., Ferroni S., and Rudolphi K. Pathological immuno-reactions of glial cells in Alzheimer's disease and possible sites of interference. J. Neural. Trans. Suppl. 54 (1998) 167-174
33. Schubert P., Ogata T., Rudolphi K., Marchini C., McRae A., and Ferroni S. Support of homeostatic glial cell signaling: a novel therapeutic approach by propentofylline. Ann. N Y Acad. Sci. 826 (1997) 337-347
34. Schubert P., and Rudolphi K. Interfering with the pathologic activation of microglial cells and astrocytes in dementia. Alzheimer Dis. Assoc. Disord. 12 Suppl. 2 (1998) S21-S28
35. Schumacher M.A., Basbaum A.I., and Way W.L. Opioid Analgesics and Antagonists. In: Katzung B.G. (Ed). Basic & Clinical Pharmacology (2004), McGraw-Hill, New York 497-516
36. Si Q.S., Nakamura Y., Schubert P., Rudolphi K., and Kataoka K. Adenosine and propentofylline inhibit the proliferation of cultured microglial cells. Exp. Neurol. 137 (1996) 345-349
37. Svensson M., Eriksson N.P., and Aldskogius H. Evidence for activation of astrocytes via reactive microglial cells following hypoglossal nerve transection. J. Neurosci. Res. 35 (1993) 373-381
38. Svensson M., Eriksson P., Persson J.K., Molander C., Arvidsson J., and Aldskogius H. The response of central glia to peripheral nerve injury. Brain Res. Bull. 30 (1993) 499-506
39. Sweitzer S.M., Martin D., and DeLeo J.A. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 103 (2001) 529-539
40. Sweitzer S.M., Schubert P., and DeLeo J.A. Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. J. Pharmacol. Exp. Ther. 297 (2001) 1210-1217
41. Tanga F.Y., Raghavendra V., and DeLeo J.A. Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochem. Int. 45 (2004) 397-407
42. Tawfik V.L., LaCroix-Fralish M.L., Bercury K.K., Nutile-McMenemy N., Harris B.T., and DeLeo J.A. Induction of astrocyte differentiation by propentofylline increases glutamate transporter expression in vitro: heterogeneity of the differentiated phenotype. Glia 54 (2006) 193-203
43. Watkins L.R., and Maier S.F. GLIA: a novel drug discovery target for clinical pain. Nat. Rev. Drug Discov. 2 (2003) 973-985
44. Watkins L.R., Milligan E.D., and Maier S.F. Glial activation: a driving force for pathological pain. Trends Neurosci. 24 (2001) 450-455